Focal cortical dysplasia (FCD) is a well-known cause of medically intractable epilepsy. To understand the potential role of the inflammatory cytokine interleukin 2 (IL-2) in the pathogenesis of FCD, we investigated the expression patterns of IL-2 and its receptors (IL-2Rs) in FCD and control samples that included epileptic neocortex from mesial temporal lobe epilepsy patients and nonepileptic normal cortex (CTX). Greater mRNA and protein levels of IL-2 and IL-2Rs were observed in FCD versus CTX samples. Moreover, the expression of IL-2 and IL-2Rs was significantly higher in FCD II than FCD I. In situ hybridization and immunohistochemistry results indicated that IL-2 and IL-2Rs were strongly expressed in hypertrophic neurons and neuronal microcolumns in FCD I and highly expressed in malformed cells in FCD II. In addition, the protein levels of Janus kinase 1, Janus kinase 3, phosphorylated signal transducer and activator of transcription 5, which are important downstream factors in the IL-2 signaling pathway, were increased in FCD lesions. Soluble IL-2R was decreased in FCD compared with that in CTX samples. These results suggest that upregulation of IL-2 and IL-2Rs combined with activation of IL-2Ydependent signaling pathways may contribute to the pathogenesis of FCD.
INTRODUCTION
Focal cortical dysplasia (FCD), which is characterized by sporadic architectural and cytoarchitectural malformations of the cerebral cortex, is the major cause of chronic medically intractable epilepsy in children (1) . According to the current classification system, isolated forms of FCD can be distinguished into type I and type II (2) . Previous studies have indicated that cortical lesions in FCD are likely to be epileptogenic foci (3) , but the molecular mechanisms underlying the pathogenesis of FCD and associated epilepsy remain unclear.
The involvement of inflammatory processes in the pathophysiology of human epilepsy has received increasing attention (4, 5) . The activation of both innate and adaptive immune responses and the upregulation of proinflammatory cytokine expression (i.e. interleukin 1A [IL-1A], IL-6, and tumor necrosis factor) have been described in human epileptogenic tissue, particularly in malformations of cortical development (1, 6, 7) . Emerging evidence supports the hypothesis that activation of the inflammatory pathway may contribute to the generation and recurrence of seizures and seizure-related neuronal damage (8, 9) . In addition to the innate immune response, several studies have demonstrated the presence of T cells in malformations of cortical development (1, 10) . T cells may exert functional roles in mesial temporal lobe epilepsy (MTLE) (11, 12) and Rasmussen encephalitis (13) , both of which are also associated with intractable epilepsy.
Interleukin 2, a cytokine also known as ''T-cell growth factor,'' exhibits a variety of biologic functions through its receptor complex and downstream signaling factors. Interleukin 2 receptors (IL-2Rs) are composed of 3 distinct subunits: IL-2R>, IL-2RA, and IL-2RF. In different combinations, these subunits can form different functional IL-2R subtypes (14) . Binding of IL-2 to the IL-2Rs mediates the activation of Janus kinase 1 (JAK1) and JAK3 (15) ; these kinases in turn result in the recruitment of the signal transducer and activator of transcription (STAT) (16) . In addition, the soluble form of IL-2R (sIL-2R) is regarded as a marker of T-cell activation that can act by binding IL-2 to compete with cell-bound IL-2Rs (17) .
In addition to multiple regulatory functions within the immune system, emerging evidence suggests that IL-2 is also a modulator of the CNS. Brain-derived IL-2 is potentially produced by neurons and astrocytes and is widely distributed throughout the brain (18) . Alterations in brain-derived IL-2 and IL-2Rs have been implicated in the pathogenesis of several major neurologic disorders, including multiple sclerosis (19) , Alzheimer disease (14) , and white matter damage (20) . Notably, intraventricular administration of IL-2 promotes seizures in various rodent models of epilepsy (21) . Furthermore, high doses of IL-2 cause recurrent seizure activity (22) ; however, to date, no reports have investigated the expression of IL-2 and its receptors in FCD lesions.
Here, we analyzed the mRNA and protein expression of IL-2, with its receptors and downstream factors, in surgically resected FCD I and FCD II cortical lesions. We also investigated the specific cellular distribution of IL-2 and its receptors in both neuronal and glial components of FCD.
MATERIALS AND METHODS

Subjects
The specimens studied were obtained from the archives of the Department of Neurosurgery at Xinqiao Hospital (the Third Military Medical University in Chongqing, China). All procedures and experiments were approved by the Ethics Committee of the Third Military Medical University, where informed consent was obtained for the use of brain tissue and medical records for research purposes. All human specimens were obtained and used in a manner compliant with the Declaration of Helsinki. No tissue was resected solely for experimental purposes.
All patients underwent presurgical evaluation and met the criteria for epilepsy surgery. We examined surgical specimens from patients with FCD I (n = 14) and FCD II (n = 12). All cases were independently reviewed by 2 neuropathologists, and the diagnosis was confirmed according to the international consensus classification system of the International League Against Epilepsy (2) . Detailed clinical data and applications performed on each patient specimen are listed in T1   Table 1 . Seizure duration represents the interval between the age at seizure onset and the age at surgery in years. The postoperative seizure outcome AQ4 ( T2 Table 2 ) was assessed according to the criteria of Engel et al (23) .
Samples from patients with MTLE, a common form of human intractable epilepsy, served as an epilepsy control group (n = 12). The detailed clinical data and applications performed on these patient samples are listed in Table, Supplemental Digital Content 1, http://links.lww.com/NEN/A555. Age-matched control cortex (CTX)/white matter samples were obtained from the autopsies of 9 patients (6 males/3 females; mean age, 6.0 years; range, 1Y13 years) without a history of seizures or other neurologic diseases. All autopsies were (24, 25) . The autopsy cases were reviewed by 2 neuropathologists, and both gross and microscopic examinations showed no structural abnormalities. In addition, 5 patients (4 with FCD I and 1 with FCD II; Table 1 ) with a sufficient perilesional zone (normal-appearing cortex/white matter adjacent to the lesion) were examined. Specimens from the last group represent optimal control tissues because they were exposed to the same seizure activities, drugs, and fixation protocol.
Tissue Preparation
All the neocortical samples obtained at surgery or autopsy were immediately divided into 2 parts. One part was fixed in 10% buffered formalin and embedded in paraffin. Paraffin-embedded tissue was sectioned at 6 Km for histologic study, in situ hybridization (ISH), and immunohistochemistry (IHC). One section from every specimen was processed for hematoxylin and eosin staining. The second part was snapfrozen in liquid nitrogen and maintained at j80-C until used for real-time polymerase chain reaction (PCR), Western blotting, and ELISA analyses.
Real-time Quantitative PCR Analysis
Real-time quantitative PCR analysis was performed using RNA prepared from freshly frozen histologically normal human cortex (n = 6) and specimens from patients with MTLE (n = 6) and FCD (type I and type II; n = 6 for each type). The RNA preparation contained equal proportions of gray and white matter tissues. Total RNA from each sample was extracted using Trizol reagent following the manufacturer's instructions (Invitrogen, La Jolla, CA). The concentration and purity of RNA were determined spectrophotometrically at 260/280 nm with a nanodrop spectrophotometer (Ocean Optics, Dunedin, FL). One microgram of total RNA was reversetranscribed into single-stranded complementary DNA with oligo (dT) primer (TakaRa, Otsu, Japan). Polymerase chain reaction primers were designed based on the complementary DNA sequence and synthesized by TaKaRa Biotechnology Company (Dalian, China). The following primers were used: IL-2 (forward: caaagaaaacacagctacaactgga; reverse: cttaaatg tgagcatcctggtga), IL-2R> (forward: cagggatacagggctctacacag; reverse: ctcttcacctggaaactgactgg), IL-2RA (forward: tagaagtgc tggagagggacaag; reverse: cgggaggtggaagaagaagtaac), IL-2RF (forward: tggagtggtgtgtctaagggact; reverse: cagtaggggctatg ctggttg), and A-actin (forward: gcaccacaccttctacaatgagc; reverse: tagcacagcctggatagcaacg). The cycling conditions for IL-2 were as follows, with any changes in the conditions used for the other primers indicated in parentheses: initial denaturation at 95-C for 3 minutes, followed by 40 cycles of denaturation at 95-C for 15 seconds and annealing elongation at 65-C for 30 seconds (IL-2R> 30 seconds at 58-C; IL-2RA 30 seconds at 58-C; IL-2RF at 58-C). The relative quantification of each product compared with the reference gene A-actin was evaluated by calculating 2 j$$Ct . All of the samples were run in triplicate, and the relative quantification of each target gene expression was performed twice.
Antibody Characterization
The primary antibodies used in this study are listed in Table, Supplemental Digital Content 3, http://links.lww.com/NEN/A557.
Western Blotting
Western blotting was performed to quantify the amount of IL-2, IL-2R>, IL-2RA, and IL-2RF and downstream molecular proteins in MTLE and FCD lesions compared with CTX. Western blot analysis was performed on frozen specimens from histologically normal CTX (n = 14), MTLE (n = 12), FCD I (n = 14), and FCD II (n = 12) brain samples. The samples were homogenized in lysis buffer containing 150 mmol/L sodium chloride, 50 mmol/L Tris-HCl pH 7.5, 10% glycerol, 1% NP-40, 0.4 mg/mL Na-orthovanadate, 5 mmol/L ethylene diamine tetra acetic acid (pH 8.0), 5 mmol/L NaF, and a 10% protease inhibitor cocktail (Sigma, St. Louis, MO). Protein concentrations were estimated using the Bradford method (Bio-Rad, Hercules, CA). Equal amounts of protein (50 Kg) were separated by 10% and 15% sodium dodecyl sulfateYpolyacrylamide gel electrophoresis to differentiate by molecular weight and were then transferred onto polyvinylidene fluoride membranes. Membranes were blocked in 5% dry milk for 1 hour and incubated overnight with primary antibody. After washing and incubating with horseradish peroxidaseYconjugated anti-rabbit or anti-mouse secondary antibodies (1:5000; Beyotime, Shanghai, China) for 1 hour at room temperature. Immunoreactivity (IR) was visualized using enhanced chemiluminescence. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was measured and used as a reference value. In Situ Hybridization
Sections from tissue blocks were routinely stained with hematoxylin and eosin, and consecutive serial sections were used for ISH and IHC. In situ hybridization was assessed using commercial detection kits (Boster, Wuhan, China) with high-performance liquid chromatography purified oligonucleotide probes that were specific for IL-2 (catalog AQ5 MK1162h), IL-2R> (catalog MK2075h), IL-2RA (catalog MK2076h), and IL-2RF (catalog MK2077h) mRNA. Briefly, paraffin sections were deparaffinized, rehydrated, and incubated with 0.3% H 2 O 2 for 30 minutes. After treatment with pepsin to expose mRNA (100 mg/mL in 3% citric acid, 30 minutes, 37-C), sections were prehybridized at 38-C for 3 hours and then hybridized with a digoxigenin-labeled oligonucleotide probe at 38-C overnight. After hybridization, the sections were washed in 2Â SSC for 5 minutes at 37-C, 0.5Â SSC for 15 minutes at 40-C, and 0.2Â SSC for 15 minutes at 42-C. The immunoreactions were visualized using a ready-to-use SABC peroxidase system (Boster) with 3,3 ¶-diaminobenzidine tetrahydrochloride hydrate (Boster) as the chromogen. Sections were counterstained with hematoxylin, dehydrated with alcohol, cleared with xylene, and placed on a coverslip. As negative controls, sections were incubated with a nonsense probe or PBS (omitting oligonucleotide probes).
Immunohistochemistry
Single-label IHC was performed using the avidin-biotin peroxidase staining method. The sections were incubated with primary antibodies overnight at 4-C. Thereafter, the sections were incubated with appropriate secondary antibodies (Boster) for 45 minutes at 37-C and then SABC peroxidase (Boster) for 30 minutes at 37-C. Immunoreactions were visualized with 3,3 ¶-diaminobenzidine tetrahydrochloride hydrate. Sections were counterstained with hematoxylin, dehydrated, and coverslipped. No immunoreactive cells were detected in negative control experiments, which included application of the secondary antibody alone, preabsorption with a 10-fold excess of a specific blocking antigen, or incubation with an isotype-matched rabbit polyclonal antibody (Figure, Supplemental Digital Content 4, http://links.lww.com/NEN/A558).
For double immunofluorescence staining, sections were incubated with mixed primary antibodies overnight at 4-C. After rinsing, the sections were incubated with a mixture of CY5-conjugated anti-mouse antibody (1:500; Jackson ImmunoResearch, West Grove, PA) and Alexa Fluor 488 anti-rabbit antibody (1:500; Molecular Probes, Eugene, OR) for 1 hour at 37-C. For negative controls, the primary antibodies were omitted. Counterstaining of cell nuclei was performed by incubating the sections with DAPI (Beyotime) for 25 minutes at room temperature. Fluorescent sections were observed and photographed using a laser scanning confocal microscope (Leica TCS-TIV, Nussloch, Germany). Images were converted to TIFF format, and contrast levels were adjusted using Adobe Photoshop 11.0 (Adobe Systems, San Jose, CA).
ELISA
The concentration of sIL-2R was measured by ELISA using commercial detection kits (Neobioscience Technology Company, Beijing, China). Histologically normal (n = 9), MTLE (n = 9), FCD I (n = 10), and FCD II (n = 10) frozen brain specimens were used for ELISA according to the manufacturer's instructions. The sensitivity of the assays for sIL-2R was 16.0 pg/mL. All of the samples from epileptic patients and controls were equally distributed across several plates to minimize potential differences.
Evaluation of Western Blot Analysis
For the Western blot analysis, densitometric analysis was performed using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD). The optical density values of each protein band were calculated and normalized to the optical density value of GAPDH.
Evaluation of IHC and Cell Counting
Evaluation of specific immunostaining and cell counting were performed by 2 independent observers. The overall concordance was greater than 90%, and the overall J value ranged from 0.83 to 0.96. Interleukin 2 and IL-2R>/A/F IR was evaluated using a Leica microscope as previously reported (26) . Each section was divided into 200 high-power nonoverlapping fields using a square grid inserted into the eyepiece (0.0625 Â 0.0625Ymm width, each corresponding to 781.250 Km 2 ). Staining intensity was evaluated using a semiquantitative 3-point scale in which IR was defined as follows: 0, absent (j); 1, weak (+); 2, moderate (++); or 3, strong (+++) staining. The intensity scores represent the predominant staining intensity found in each section and were calculated as an average across the selected fields ( T3 Table 3 ). The labeling index of IL-2 and IL-2RYpositive malformed cells (MCs) in the FCD lesions, which includes hypertrophic neurons (HNs), dysmorphic neurons (DNs), and balloon cells (BCs), was calculated as previously described (26) . Malformed cells can be clearly distinguished by their characteristic cytologic properties. Only cells that could be clearly identified as MCs were included in the analysis. The total number of MCs (N 1 ) and immunoreactive-positive MCs (N 2 ) was calculated for each serial section. The labeling index was calculated as follows: (N 2 / N 1 ) Â 100%. For each case, the values from 3 sections in each paraffin block were averaged, and this average value was defined as the ratio of immunolabeled cells relative to the entire cell population of interest ( T4 Table 4 ).
Data Analysis and Statistics
Data are expressed as the mean T SE. SPSS for Windows (SPSS, Inc., Chicago, IL) was used for the statistical analysis. Means were compared using an analysis of variance (ANOVA), and differences between groups were considered significant for values of p G 0.05.
RESULTS
Case Material and Histologic Features
Normal-appearing cortical samples exhibited organized layers, with well-preserved laminations, unipolar orientation of apical dendrites toward the pial surface, and normal definition of the gray-white matter junction. None of the FCD cases were associated with other 
Interleukin 2 mRNA Expression
There was greater IL-2 mRNA expression in epilepsy groups compared with CTX ( F1   Fig. 1A ). The IL-2 mRNA level was significantly higher in FCD II vs. FCD I. No significant differences were observed between MTLE and FCD (FCD I and FCD II) specimens. In situ hybridization analysis was performed to study the cellular distribution of IL-2 mRNA in CTX and FCD specimens. Histologically normal cortex displayed IL-2 mRNA expression in pyramidal neurons and glial cells (Fig. 1B) . In FCD I, moderate to strong IL-2 mRNA expression was detected in HNs and in microcolumns (Fig. 1C) . In FCD II there was strong IL-2 mRNA expression in MCs (Fig. 1D ).
IL-2 Western Blot and IHC Analysis
Consistent with the results obtained by real-time PCR, Western blot analysis showed increased IL-2 protein levels in the epilepsy group compared with CTX ( F2 Fig. 2A, B) . The IL-2 protein level was significantly higher in FCD II versus those in FCD I and MTLE cases. In addition, IL-2 protein expression was higher in FCD I than those in MTLE cases. The distribution and cellular pattern of IL-2 IR in pyramidal neurons and glia in the CTX samples were similar to those in previous reports (Fig. 2C, F) (18) . The immunostaining intensity scores indicated a higher expression of IL-2 in the MTLE and FCD specimens versus those in the CTX samples (Table 3) .
In FCD I, IL-2 was intensely expressed in microcolumns (Fig. 2D) and in 79.7% T 1.9% (n = 220) of HNs. Double labeling experiments revealed colocalization of IL-2 IR with NeuN in HNs and normal-appearing neurons (Fig. 2I) . Interleukin 2 was coexpressed with GFAP in reactive astrocytes (Fig. 2J) . In FCD II, 76.9% T 2.6% of HNs (n = 470), 78.7% T 2.4% of DNs (n = 560), and 70.0% T 3.4% of BCs (n = 389) distributed from the pial surface to the subcortical white matter displayed IL-2 immunostaining (Fig. 2E, H) . Interleukin 2 IR was also observed in normal-appearing neurons and cells exhibiting glial morphology in FCD lesions. Double labeling experiments confirmed colocalization of IL-2 IR with NeuN in MCs (Fig. 2K ) and with GFAP in reactive astrocytes (Fig. 2L ). In agreement with the abnormal differentiation of the BCs, we observed colocalization of IL-2 IR with vimentin in BCs (Fig. 2L insert) . Further experiments revealed that T cells (CD3 positive) within the dysplastic cortex occasionally displayed IL-2 IR (Fig. 2N ), but no HLADRYpositive microglia in FCD lesions showed positive immunostaining of IL-2 (Fig. 2M ).
IL-2R mRNA Expression
No significant differences in IL-2R> mRNA expression were observed between the CTX, MTLE, and FCD I specimens ( F3 Fig. 3A) . Interleukin 2R> levels were significantly higher in FCD II versus those in the other groups. There was greater IL-2RA and IL-2RF mRNA expression in the epilepsy groups compared with that in the CTX group. The IL-2RA mRNA level was significantly higher in FCD II and MTLE specimens versus those in FCD I specimens, and MTLE and FCD II were not significantly different. The IL-2RF mRNA level was significantly higher in FCD II versus those in the MTLE and FCD I specimens, and MTLE and FCD I were not significantly different.
In situ hybridization analysis showed the cellular distribution of IL-2R>, IL-2RA, and IL-2RF mRNA in CTX and FCD samples. Weak to modest IL-2R subunit mRNA expression was observed in pyramidal neurons and glial cells in CTX (Fig. 3B, E, H) . In FCD I, there was moderate to strong IL-2R>, IL-2RA, and IL-2RF mRNA expression in HNs and microcolumns (Fig. 3C, F, I ). In FCD II, there was strong IL-2R>, IL-2RA, and IL-2RF mRNA expression in MCs (Fig. 3D, G, J) .
IL-2R Western Blot and IHC
Larger IL-2R> protein levels were obtained by Western blot analysis in the epilepsy groups compared with those in the CTX group ( Fig. 4A, B) . The IL-2R> protein level was significantly higher in MTLE versus those in FCD specimens. No significant difference was observed between FCD I and FCD II specimens. The IL-2RA protein level was significantly higher in FCD II versus those in the other groups.
Greater IL-2RA protein expression was detected in MTLE compared with CTX and FCD I, and CTX and FCD I were not significantly different. The IL-2RF protein level was significantly higher in FCD than those in CTX and MTLE samples. Increased IL-2RF protein expression was detected in FCD II compared with that in FCD I, and no significant difference was observed between CTX and MTLE specimens.
Weak to moderate IL-2R>, IL-2RA, and IL-2RF IR was detected in pyramidal neurons and glial cells in CTX samples (Figs. 4C, F; 
F5
5A, D;
F6 6A, D). The cellular pattern of IL-2Rs in normal cortex was consistent with those in previous reports (27) . The intensity scores of IL-2R>, IL-2RA, and IL-2RF IR in the MTLE and FCD specimens were dramatically higher than those in the CTX samples (Table 3) .
In MTLE specimens, there was moderate to strong IL-2 staining detected in neurons and glial cells ( (Fig. 7B ) and with GFAP in reactive astrocytes (Fig. 7C) . Moderate to strong IL-2R>, IL-2RA, and IL-2RF staining was detected in neurons and glial cells in MTLE specimens (Fig. 7D, G, J) . Double labeling experiments demonstrated colocalization of IL-2R>, IL-2RA, and There is weak to moderate IL-2 mRNA expression in CTX; the signal is restricted to pyramidal neurons (arrows) and glia-like cells (arrowheads) (B). There is moderate IL-2 mRNA expression in microcolumns (double arrows) in FCD I; the insert shows a highmagnification view of hypertrophic neurons (C). There is strong IL-2 mRNA expression in balloon cells (arrow) and in dysmorphic neurons (arrowheads). Diaminobenzidine was applied as the chromogen; the sections were counterstained with hematoxylin. Scale bar = 50 Km.
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2014 American Association of Neuropathologists, Inc. (Fig. 7E , H, K) and with GFAP in reactive astrocytes (Fig. 7F, I , L). In FCD I, moderate to strong IL-2R>, IL-2RA, and IL-2RF staining was detected in microcolumns (Figs. 4D , 5B, 6B) and 80.8% T 1.6% (n = 179), 81.9% T 1.4% (n = 301), and 80.6% T 1.9% (n = 233) of HNs, respectively. Double labeling experiments revealed colocalization of IL-2>, IL-2A, and IL-2F IR with NeuN in HNs and normal-appearing neurons (Figs. 4I, 5G, 6G ). Interleukin 2R>, IL-2RA, and IL-2RF were coexpressed with GFAP in reactive astrocytes (Figs. 4J,  5H, 6H) .
IL-2RF IR with NeuN in neurons
In FCD II, 73.6% T 2.3% of HNs (n = 505), 81.8% T 3.6% of DNs (n = 511), and 75.1% T 3.0% of BCs (n = 330) displayed IL-2R> staining; 81.1% T 1.6% of HNs (n = 533), 82.9% T 2.1% of DNs (n = 600), and 75.9% T 3.5% of BCs (n = 410) displayed IL-2RA staining; and 78.6% T 2.6% of HNs (n = 410), 80.4% T 2.4% of DNs (n = 460), and 72.6% 
JAK1, JAK3, and p-STAT5 Expression
Interleukin 2 mediates the activation of several major signaling pathways, including the Janus kinaseYsignal transducer and activator of transcription (JAK/STAT) pathway. Janus kinase 1 and JAK3 in turn mediate the activation of STAT5. We previously investigated STAT3 in FCD (28) . Here, we investigated the other downstream factors involved in the JAK/STAT pathway, that is, JAK1, JAK3, and p-STAT5. Western blot analysis revealed that the protein levels of JAK1, JAK3, and p-STAT5 were significantly higher in the epilepsy groups than the CTX group. Moreover, the protein levels were significantly higher in FCD II versus those in FCD I and MTLE. In addition, JAK1 and p-STAT5 protein levels were higher in FCD I than those in MTLE; however, JAK3 protein levels in MTLE and FCD I were not significantly different ( F8 Fig. 8 ).
Soluble IL-2R ELISA
Soluble IL-2R levels in FCD specimens were lower than those in CTX samples (FCD I vs CTX, p G 0.05; FCD II vs CTX, p G 0.05) ( F9 Fig. 9 ). In contrast, the sIL-2R level in MTLE was slightly lower than those in CTX samples (Fig. 9 ), but this difference was not significant (p 9 0.05).
DISCUSSION
The involvement of inflammatory processes in the pathophysiology of human epilepsy has received increased attention in recent years. Interleukin 2 is a cytokine that is mainly produced by activated T cells, and it has multiple immunoregulatory functions that are related to T cells and the CNS (18, 29) . In the present study, upregulated expression patterns of IL-2 and its receptors were detected in MTLE and cortical lesions of FCD compared with those in histologically normal CTX samples at both the mRNA and protein levels. Intriguingly, ISH and IHC results demonstrated that the high-level expression of mRNA and protein, including IL-2 and its receptors, was mainly localized within microcolumns and MCs, including HNs, DNs, and BCs. In addition, the protein levels of important downstream factors in the IL-2 pathway, JAK1, JAK3, and p-STAT-5, were significantly increased in MTLE and FCD specimens versus those in CTX samples. One disadvantage of the use of CTX samples from postmortem brains is autolysis. Thus, the use of high-quality samples from rapidly performed autopsies (i.e. within 6 hours of death) was important in the present study.
IL-2 and IL-2Rs in CTX
Previous studies have demonstrated IL-2 and IL-2Rs in human (30, 31) and rodent brains (32) . In histologically normal brains, the IL-2/IL-2R system was localized in many regions, with neurons and glial cells being potential sources (33) . In the present study, we detected IL-2 and IL-2R>, IL-2RA, and IL-2RF mRNA and protein expression in CTX samples using real-time PCR and Western blotting. In situ hybridization and IHC results revealed weak to moderate IL-2/IL-2R expression in pyramidal neurons and glial cells in these samples.
Enhanced Expression of IL-2 in FCD
The IL-2 signaling system has been implicated in several neurologic disorders, including hypoxia-ischemia brain injury (32) , Tourette syndrome (24), multiple sclerosis (19, 34) , white matter damage (20) , and Parkinson disease (30), but little is known about the cellular sources of IL-2 detected in these brains. In the present study, we detected greater IL-2 mRNA and protein levels in tissue homogenates of FCD versus those in CTX specimens. In addition, ISH and IHC results displayed high levels of IL-2 expression in MCs, microcolumns, and normal-appearing neurons in FCD lesions, indicating that these cells could be the sources of IL-2. Although a previous study suggested that microglia might be the source and target of IL-2 (35), we did not detect any microglia in FCD lesions showing IL-2 IR. In contrast, we detected IL-2 in T cells and reactive astrocytes, indicating that brain-infiltrating T cells and reactive astrocytes could be sources of IL-2.
To our knowledge, the induction of IL-2 by seizures has not previously been demonstrated, but the effect of IL-2 on seizures has been previously assessed. Intraventricular administration of IL-2 facilitates seizures in rodent models by decreasing the latency to epileptiform discharges and increasing the duration of seizure activity (21, 22) . Furthermore, high doses of IL-2 could cause recurrent seizure activity (5) . These results suggest that the increased IL-2 levels in the epilepsy group may have contributed to the intrinsic and high epileptogenicity of FCD and MTLE. Interestingly, plasma and cerebrospinal fluid IL-2 levels were unchanged in patients with prolonged febrile seizures (36) , suggesting that seizures alone might not account for the increased IL-2 expression in FCD and MTLE. Therefore, the lesion per se or the coexistence of the lesion and seizure activity likely results in modulation of the IL-2 system in FCD and MTLE.
Enhanced Expression of IL-2 Receptors in FCD
Interleukin 2RA and IL-2RF are critical for signal transduction, whereas IL-2R> augments binding affinity but does not contribute to IL-2 signal transduction (16). We detected greater mRNA and protein levels of IL-2R>, IL-2RA, and IL-2RF in cortical lesions of FCD patients. Interleukin 2R>, IL-2RA, and IL-2RF IR was mainly located in MCs and T cells. The similar expression patterns for IL-2 and IL-2R>, IL-2RA, and IL-2RF suggest that IL-2 may function through an autocrine/paracrine mechanism on MCs and T cells.
The neuroprotective effect mediated by IL-2 has been well recognized. Interleukin 2 enhances the viability and survival of cortical neurons (37, 38) . Moreover, IL-2 significantly promotes the elongation and branching of neurites in hippocampal neurons (39) . These data support the hypothesis that the IL-2 signaling system may protect MCs from cell death in the cortical lesion of FCD through an autocrine/ paracrine mechanism.
Interleukin 2 exhibits a variety of functions related to T-cell migration, proliferation, and survival; it has long been recognized as a chemoattractant for T cells (40) . Interleukin 2 can upregulate the expression of CC chemokine receptors and adhesion molecules that mediate the recruitment of activated T cells and their infiltration into tissues (41) . More importantly, intracerebroventricular administration of IL-2 led to T-cell invasion of the brain (42) . In addition, continued exposure to IL-2 prevented apoptosis in activated T cells by upregulating Bcl-2 protein (43). These results suggest that the infiltrating T cells could be a target of IL-2, which may modulate chemotaxis and the survival of these T cells, thereby contributing to the inflammatory state of the epileptic brain.
Soluble IL-2R
Lower sIL-2R levels were detected in FCD compared with those in CTX samples. A slightly, but not significantly, reduced sIL-2R level was found in MTLE versus that in CTX. Soluble IL-2R may compete with membrane-bound receptors for IL-2 and thus exert an antagonist effect on the IL-2 signal. We speculate that decreased sIL-2R concentrations likely reinforce the bioavailability of IL-2, and that this might represent an underlying mechanism of pathogenesis in FCD.
JAK-STAT Pathway
It has been well established that IL-2 could be responsible for activation of 3 major signaling pathways, including the JAK/STAT, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways. Attention has been focused on activation of the phosphatidylinositol 3-kinase (44, 45) and mitogen-activated protein kinase (46) signaling pathways, both of which likely contribute to the pathogenesis and histopathologic features of malformations of cortical development. Therefore, to determine whether IL-2 signaling is mediated via the IL-2Rs/JAK/STAT pathway, we analyzed the changes in JAK1, JAK3, and p-STAT5 expression in MTLE and FCD relative to those in CTX samples. Markedly greater JAK1, JAK3, and p-STAT5 protein levels were detected in MTLE and FCD versus those in CTX specimens, indicating that activation of the IL-2Rs/JAK/STAT pathway could potentially be involved in IL-2Ydependent pathogenesis of MTLE and FCD. However, it should be noted that IL-2RA is shared by IL-2 and IL-15 and that the IL-2RF is a common subunit of receptor complexes for all of the IL-2 family cytokines (including IL-4, IL-7, IL-9, IL-15, and IL-21) (47). To date, no reports have investigated the expression of these cytokines in FCD, which might also trigger the activation of the IL-2Rs/JAK/STAT pathway in FCD lesions. Therefore, further investigation is required to clarify the direct contribution of IL-2 to the activation of the IL-2Rs/JAK/STAT pathway in FCD lesions.
The following limitations should be noted in interpreting our results. First, age-unmatched MTLE specimens were used as a control group. We were apprehensive that the age and (or) the seizure duration might influence the expression of IL-2. Thus, we investigated the mRNA and protein levels of IL-2 in pediatric MTLE specimens (n = 5; mean age, 9.2 years; range, 7Y13 years; Table, Supplemental Digital Content 6, http://links.lww.com/NEN/A560), and no difference was detected compared with those in adult MTLE specimens (Figure, Supplemental Digital Content 7, http://links.lww.com/NEN/A561). Second, we observed differences between mRNA and protein expressions of IL-2 and receptors. The reasons for these differences remain unclear, but we assume that it might in part be caused by the regulatory Fig 9 4/C   FIGURE 9 . Levels of soluble interleukin 2 receptor (sIL-2R) in tissue from control cortex (CTX), mesial temporal lobe epilepsy (MTLE), focal cortical dysplasia type I (FCD I), and FCD II specimens. The levels of sIL-2R in FCD I (n = 10; mean, 6.42 pg/mg protein; range, 3.12Y11.41 pg/mg protein) and FCD II (n = 10; mean, 2.66 pg/mg protein; range, 0.74Y4.64 pg/mg protein) were significantly lower than those in the CTX tissues (n = 9; mean, 12.88 pg/mg protein; range, 9.42Y16.01 pg/mg protein). Levels of sIL-2R in MTLE (n = 9; mean, 10.56 pg/mg protein; range, 7.98Y14.63 pg/mg protein) were slightly lower than those in CTX, but the difference was not significant. Third, the present study only includes specimens from FCD Ia and FCD IIb patients; therefore, the issue of whether the induction of IL-2 and its receptor expression also occurs in FCD Ib and FCD IIa still needs to be clarified.
In conclusion, our findings demonstrate a strong association between overproduction and overexpression in the IL-2 signaling system and FCDs. The high expression of IL-2 signaling in microcolumns and various MCs indicates that different cellular components of dysplastic cortex are involved in the IL-2 signaling system. The underlying mechanisms of IL-2 signaling system in the pathogenesis of FCDs could not be elucidated because of the limitations of a human study. Further studies are required to evaluate the biologic significance of altered IL-2 signaling system expression and distribution within the dysplastic cortex.
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